Exchange: NASDAQ·Updated 07:38 PM EDT

INVA News

News
all
press releases
INVA vs. MRK: Which Stock Is the Better Value Option?
INVA vs. MRK: Which Stock Is the Better Value Option?
Zacks
INVA vs. MRK: Which Stock Is the Better Value Option?
INVA vs. MRK: Which Stock Is the Better Value Option?
Zacks
More News
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
DINO, INVA, PARR, GNW and PBF stand out as low price-to-sales stocks with promising upside potential. Discover how attractive valuations can uncover hidden value.
Zacks
Should Value Investors Buy Innoviva (INVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Innoviva to Participate in Upcoming Investor Conferences
Innoviva, Inc. (NASDAQ: INVA) (Innoviva or the Company), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets...
Business Wire
Innoviva Specialty Therapeutics Antimicrobial Therapies, XACDURO, ZEVTERA and NUZOLVENCE Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the companys infectious disease therapies, XACDURO (sulbactam/durlobactam for injection), ZEVTERA (ceftobiprole medocaril sodium for injection), and NUZOLVENCE (zoliflodacin) are...
Business Wire
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Innoviva (INVA) delivered earnings and revenue surprises of +5.36% and +5.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva, Inc. (NASDAQ: INVA) (Innoviva or the Company), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets...
Business Wire
Merck (MRK) Reports Q2 Loss, Beats Revenue Estimates
Merck (MRK) delivered earnings and revenue surprises of +50.00% and +1.69%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks

Advertisement|Remove ads.